Evidence map›Paper›PMID 24971465›Full record

ArticleCancer biology & therapy2014

Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer.

Yifeng Fang, Hong Yu, Xiao Liang, Junfen Xu, Xiujun Cai

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 159 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yifeng FangThe Second Department of General Surgery; Sir Run Run Shaw Hospital; School of Medicine; Zhejiang University; Hangzhou, Zhejiang, PR China.
Hong YuThe Second Department of General Surgery; Sir Run Run Shaw Hospital; School of Medicine; Zhejiang University; Hangzhou, Zhejiang, PR China.
Xiao LiangThe Second Department of General Surgery; Sir Run Run Shaw Hospital; School of Medicine; Zhejiang University; Hangzhou, Zhejiang, PR China.
Junfen XuDepartment of Gynecologic Oncology; Women's Hospital; School of Medicine; Zhejiang University; Hangzhou, Zhejiang, PR China.
Xiujun CaiThe Second Department of General Surgery; Sir Run Run Shaw Hospital; School of Medicine; Zhejiang University; Hangzhou, Zhejiang, PR China.
Sir Run Run Shaw Hospital · CNZhejiang University · CNSecond Hospital of Nanchang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high morbidity and mortality of colorectal cancer pose a significant public health problem worldwide. Here we assessed the pro-cancer efficacy and mechanism of action of CCNB1 in different colorectal cancer cells. We provided evidence that CCNB1 mRNA and protein level were upregulated in a subset of human colorectal tumors, and positively correlated with Chk1 expression. Repression of Chk1 caused a significant decrease in cell proliferation and CCNB1 protein expression in colorectal cancer cells. Furthermore, downregulation of CCNB1 impaired colorectal cancer proliferation in vitro and tumor growth in vivo. Specifically, suppression of CCNB1 caused a strong G 2/M phase arrest in both HCT116 and SW480 cells, interfering with the expression of cdc25c and CDK1. Additionally, CCNB1 inhibition induced apoptotic death in certain colorectal cancer cells. Together, these results suggest that CCNB1 is activated by Chk1, exerts its oncogenic role in colorectal cancer cells, and may play a key role in the development of a novel therapeutic approach against colorectal cancer.

Indexed as

AnimalsApoptosisApoptosis Regulatory Proteinscdc25 PhosphatasesCDC2 Protein KinaseCell Line, TumorCell ProliferationCheckpoint Kinase 1Colorectal NeoplasmsCyclin B1Cyclin-Dependent KinasesDown-RegulationG2 Phase Cell Cycle CheckpointsGene Knockdown TechniquesHeterograftsHumansApoptosis Regulatory ProteinsCCNB1 protein, humanCDC25C protein, humancdc25 PhosphatasesCDC2 Protein KinaseCDK1 protein, humanCheckpoint Kinase 1CHEK1 protein, humanChek1 protein, mouseCyclin B1Cyclin-Dependent KinasesProtein KinasesapoptosisCCNB1cell cyclecell growthChk1colorectal cancer

Identifiers

PMID24971465
PMCPMC4128869
OpenAlexW2042844479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.